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Purpose: To describe the involvement of the lacrimal gland (LG) in blepharophimosis-ptosis-epicanthus
inversus syndrome (BPES).
Design: Observational, cross-sectional study.
Participants: Twenty-one patients with BPES (10 female, 11 male) aged on average 15 years (range,
2e39 years), from 3 Brazilian medical centers and 1 Portuguese medical center.
Methods: Patients had their ocular surface evaluated with slit-lamp biomicroscopy, and tear production
quantiﬁed with the Schirmer test I. The LG volumes were measured on computed tomography (CT) scans in the
BPES sample and in a group of age-matched subjects imaged for nonorbital diseases. Sixteen patients were
screened for mutations in the FOXL2 gene.
Main Outcome Measures: Lacrimal meniscus height, Schirmer test I, presence of superﬁcial punctate
keratopathy (SPK), LG volume, and molecular analysis of the FOXL2 gene.
Results: Absence of LG was detected bilaterally in 9 patients (42.8%) and unilaterally in 2 patients (9.5%).
When considering only patients with measurable LG, the median volume was 0.22 cm3 in the right eye (range,
0.06e0.36 cm3) and 0.24 cm3 in the left eye (range, 0.08e0.34 cm3). These values were signiﬁcantly lower than
those for the age-matched controls (median ¼ 0.54 right eye and 0.53 left eye; P < 0.05). There was a signiﬁcant
association between deﬁciency of tear production and LG volume reduction and agenesis. Molecular analysis of
the FOXL2 gene revealed the presence of 8 distinct mutations, 4 of them novel ones. A signiﬁcant reduction of LG
size or agenesis was associated with mutations affecting protein size (due to underlying changes in the stop
codon location) or the DNA-binding forkhead domain (Fisher exact test, P ¼ 0.021). In 3 probands, the underlying
genetic defect was not found.
Conclusions: This is the ﬁrst study reporting LG volumes in BPES, describing a signiﬁcant number of patients
with LG agenesis. The association between alacrima and BPES is not incidental, and a thorough evaluation of tear
production is recommended especially if ptosis surgery is planned. Ophthalmology 2017;124:399-406 ª 2016 by
the American Academy of OphthalmologyBlepharophimosis-ptosis-epicanthus inversus syndrome
(BPES) (Online Mendelian Inheritance in Man 110100) is
an uncommon disorder ﬁrst described in 1889 by Vignes.1
Three decades later, Dimitry2 deﬁned its inheritance
pattern as autosomal dominant, which was conﬁrmed over
subsequent years. Its molecular basis remained
undetermined until 2001, when Crisponi et al3 ﬁnally
identiﬁed forkhead box protein L2 (FOXL2) (Online
Mendelian Inheritance in Man *605597) on chromosome
3q23 as the causal gene.3 This single-exon gene encodes a
forkhead transcription factor expressed in the developing
eyelid mesenchyme and fetal and adult ovaries.4,5 Thus,
depending on its expression, there are 2 types of BPES: type
I with premature ovarian failure and type II with normal
ovary function.6,7 Severe ptosis with poor levator function,
epicanthus inversus, and telecanthus are present in both
types. We describe a signiﬁcant spectrum of lacrimal gland
(LG) changes in BPES. In addition, molecular analysis ofª 2016 by the American Academy of Ophthalmology
Published by Elsevier Inc.FOXL2 was performed in 16 patients in an attempt to obtain
new insights into a possible genotypeephenotype
correlation.Methods
Patients
The research adhered to the tenets of the Declaration of Helsinki.
Approval was obtained from the Institutional Review Boards and
Ethics Committees, and all subjects gave written informed consent
to participate in the study.
Twenty-one patients with a clinical diagnosis of BPES were
recruited from 1 Portuguese and 3 Brazilian medical centers. Mean
age was 15 years (range, 2e39 years). Schirmer test I (without
anesthesia) and slit-lamp biomicroscopy assessment of the lacrimal
meniscus height and corneal ﬂuorescein staining were performed in
all patients. A Schirmer’s test score <10 mm after 5 minutes with399http://dx.doi.org/10.1016/j.ophtha.2016.10.028
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Table 1. Primers Used for Ampliﬁcation and Sequencing of the Entire Coding Region of the FOXL2 Gene
Primer Names Primer Sequences (5’>3’) Size of the PCR Product (bp) Annealing Temperature (

C)
FOXL2-1.1F TTTGAGACTTGGCCGTAAGC 444 55
FOXL2-1.1R TGATGAAGCACTCGTTGAGG
FOXL2-1.2F CGAAGTTCCCGTTCTACGAG 576 57
FOXL2-1.2R CCAGGCCATTGTACGAGTTC
FOXL2-1.3F GTACACACGCGTGCAGAGC 407 57
FOXL2-1.3R CGTCCCTGCATCCTCGCATC
bp ¼ base pair; PCR ¼ polymerase chain reaction.
Ophthalmology Volume 124, Number 3, March 2017the eyes closed was considered as an indication of reduced aqueous
tear production.8,9 Two radiologists measured LG volumes on
computed tomography (CT) scans using OsiriX software (devel-
oped by Pixmeo, SARL, Geneva; http://www.osirix-viewer.com)
as the Digital Imaging and Communications in Medicine (DICOM)
viewer. Brieﬂy, as described by Bingham et al,10 the LG area was
measured from consecutive axial slices of orbital CT scans and
added to obtain a ﬁnal volume. The same protocol was applied
to a group of 30 age-matched patients imaged for nonorbital pa-
thology, which constituted the control group. The Wilcoxon
signed-rank test was used to compare right and left LG volumes,
and the ManneWhitney test was used to compare LG volumes
between groups. The ManneWhitney U test was used to compare
the Schirmer’s test scores between eyes with nonmeasurable versus
reduced LG. Finally, the Fisher exact test was used to analyze the
association between the signs of keratopathy and LG size catego-
rized as reduced and nonmeasurable. In all these tests, a P value
0.05 was considered signiﬁcant.
DNA Ampliﬁcation and Exon Sequencing
Sixteen patients were submitted to exon sequencing of the FOXL2
gene. Genomic DNA was extracted from peripheral blood leuko-
cytes using a QIAamp DNA Blood isolation kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. For the
analysis of the FOXL2 gene, 3 pairs of primers were designed to
cover the entire FOXL2 exon and its splice site junctions (Table 1).
The polymerase chain reactioneampliﬁed DNA fragments were
subjected to direct sequencing using the automatic capillary
sequencing system ABI 3500X Genetic Analyzer (Applied
Biosystems, Foster City, CA) and the Big Dye terminator v3.1
cycle sequencing kit (Applied Biosystems) according to the
manufacturer’s instructions. The results were analyzed using
the FinchTV version 1.4.0 software (Geospiza, Seattle, WA); the
sequences obtained were compared with the reference from
GenBank database (NM_023067), and the mutation
nomenclature was used according to Human Genome Variation
Society guidelines (http://www.hgvs.org/mutnomen). Pathogenic
scores for missense mutations were calculated using the
prediction tools SIFT,11 MutPred,12 and MutationTaster.13
GenotypeeLacrimal Gland Phenotype
Correlation
To identify a possible genotypeephenotype correlation, 2 groups
of mutations were considered: those affecting protein size or its
functional domain and those not affecting the protein catalytic
domain or its structure. Fisher exact test was used to determine the
signiﬁcance of the association between these 2 categories of
mutations and LG abnormalities. A P value 0.05 was considered
signiﬁcant.400Results
Clinical and molecular data are shown in Table 2. Eight of the 21
patients were relatives belonging to 4 distinct families. Patients
1 and 2, 13 and 14, and 15 and 16 were progenitor and
offspring, respectively, and patients 18 and 19 were twin
brothers. Fifteen patients (71.4%) had already been submitted to
some surgical procedure to correct their eyelid malformations. In
9 patients (42.8%), more than 1 procedure had been performed,
including multiple revisions of silicone or autologous fascia
slings for ptosis surgery. Twenty-two eyes (52.4%) from 12
patients showed clinical signs of reduced tear production
manifested as decreased lacrimal meniscus height, low values on
the Schirmer test, or superﬁcial punctate keratopathy (SPK) of
variable severity. Of these 22 eyes, 20 (90.9%) did not have a
measurable LG ipsilaterally, and in the remaining 2 eyes, the LG
size was markedly reduced.
A signiﬁcant difference was found between the Schirmer’s
scores in absent versus reduced LG cases (P ¼ 0.0006). Figure 1
shows the distribution of Schirmer’s scores versus LG volumes.
Eleven of the 14 eyes (78.6%) with absent LG showed
Schirmer’s values below the 10-mm cut off. In the group with
reduced LG volumes, the Schirmer’s scores were highly variable
ranging from 3 to 35 mm. All the patients with normal LG
presented normal Schirmer’s values. A Schirmer’s score less than
10 mm had a sensitivity of 68.4% to identify an LG volume of less
than 0.20 cm3 (Fig 1). Finally, the Fisher exact test revealed that
the presence of SPK was signiﬁcantly associated with an absent
LG (P ¼ 0.0007).
Orbital CT scans disclosed LG agenesis in 11 patients, 9
(42.8%) bilaterally and 2 unilaterally. Figure 2 shows examples of
the morphologic LG variants detected. With the exception of 3
patients (6 glands), all LG volumes were reduced and below the
minimum value measured in the control group (Table 2). In
regard to only patients with BPES with measurable LG (Fig 3),
median LG volumes were 0.22 cm3 (range, 0.06e0.36 cm3) and
0.24 cm3 (range, 0.08e0.34 cm3) concerning the right and left
sides, respectively, with no signiﬁcant difference between sides
(P ¼ 0.72). In the control group, median LG volumes were 0.54
cm3 in the right orbits (mean 0.55 cm3; standard deviation, 0.19;
range, 0.30e1.22) and 0.54 cm3 in the left orbits (mean, 0.53;
standard deviation, 0.20; range, 0.32e1.29), values similar to
those previously reported in the literature.10 The ManneWhitney
test showed that the volumes of patients with BPES were
signiﬁcantly lower than in the control (P < 0.05) for both the
right and left orbits.Molecular Investigation
Molecular screening of the FOXL2 gene showed pathogenic
sequence variants in 13 (81.2%) of the 16 patients analyzed (Fig 4;
Table 2. Clinical, Imaging, and Molecular Analysis of Patients with Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome
Lacrimal Film Evaluation Lacrimal Gland Imaging FOXL2 Molecular Analysis
Patient
Age
(yrs) Gender
No. of Previous
Surgeries Laterality
Lacrimal
Meniscus
Schirmer
I (mm)
Superﬁcial
Keratopathy
Glandular
Volume (cm3)
Lacrimal Gland
Size Rating* cDNA Protein Type
1 14 F 1 R þ 18 N 0.24 Reduced c.672_701dup30 p.A224-A234dup In-frame duplication
L þ 24 N 0.28 Reduced
2 38 F None R þ 15 N 0.26 Reduced c.672_701dup30 p.A224-A234dup In-frame duplication
L þ 17 N 0.29 Reduced
3 11 F 3 R Y 15 Diffuse NM Absent Not detected X X
L Y 12 Diffuse NM Absent
4 11 M 2 R Y 2 Inferior NM Absent Not detected X X
L þ 12 N 0.24 Reduced
5 13 M 1 R þ 32 N 0.29 Reduced c.650C>G p.S217C Missense
L þ 35 N 0.25 Reduced
6 19 F 2 R þ 23 N 0.36 N Not detected X X
L þ 18 N 0.34 N
7 10 F 1 R þ > 35 N 0.32 N c.672_701dup30 p.A224-A234dup In-frame duplication
L þ > 35 N 0.32 N
8 8 M 2 R Y 7 Inferior NM Absent c.292T>G p.Y98G Missense
L Y 11 Inferior NM Absent
9 3 F 1 R þ Unc N 0.11 Reduced c.172_176delTCGTA p.S58RfsX36 In-frame deletion
L þ Unc N 0.08 Reduced
10 2 F None R Y Unc Unc NM Absent c.919_920insACCGCCGC p.P307HFsX52 In-frame insertion
L Y Unc Unc NM Absent
11 9 M 2 R Y 3 Inferior 0.17 Reduced c.370A>T p.K124Stop Nonsense
L Y 4 Inferior 0.12 Reduced
12 2 M None R Y Unc Unc NM Absent c.768-769insG p.P257AFs In-frame insertion
L Y Unc Unc NM Absent
13 39 M None R Y 3 N NM Absent c.313A>C p.N105H Missense
L Y 4 N NM Absent
14 5 F None R Y Unc Unc NM Absent c.313A>C p.N105H Missense
L Y Unc Unc NM Absent
15 36 M 2 R þ 22 N 0.12 Reduced c.672_701dup30 p.A224-A234dup In-frame duplication
L þ 32 N 0.14 Reduced
16 8 M 5 R þ Unc N 0.06 Reduced c.672_701dup30 p.A224-A234dup In-frame duplication
L þ Unc N 0.16 Reduced
17 7 F 1 R þ 18 N 0.10 Reduced Not performed
L þ 6 Inferior NM Absent
18 27 M 2 R þ 4 Inferior NM Absent Not performed
L Y 0 Inferior NM Absent
19 27 M 2 R Y 0 Inferior NM Absent Not performed
L Y 0 Inferior NM Absent
20 31 F None R NP NP N 0.32 N Not performed
L NP NP N 0.33 N
21 2 F 1 R Y 0 Inferior NM Absent Not performed
L Y 8 N NM Absent
F ¼ female; L ¼ left eye; M ¼ male; N ¼ normal; NM ¼ not measurable; NP ¼ not performed; R ¼ right eye; þ ¼ present; Y¼ visibly decreased; Unc ¼ uncooperative.
*Comparative analysis with the control group: reduced when below and N when above the minimum value measured in the control group.
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Figure 1. Distribution of Schirmer I test with lacrimal gland (LG)
volumes.
Ophthalmology Volume 124, Number 3, March 2017Table 2). Eight distinct mutations were found, 4 of them previously
unreported.
The most frequent mutation in this study was the in-frame
duplication of 30 nucleotides, c.672_701dup30, resulting in a
polyalanine expansion (p.A224-A234dup) that was detected in 5
patients (patients 1, 2, 7, 15, and 16) from 3 distinct families. Three
missense mutations also were detected (c.650C>G, c.292T>G,
c.313A>C), the last 2 in the DNA-binding forkhead domain of
the gene.
Two in-frame insertions (c.919_920insACCGCCGC and
c.768-769insG), a nonsense mutation (c.370A>T), and an in-frame
deletion (c.172_176delTCGTA) were also found. All 4 interfered
with the stop codon position; 3 of them led to a premature stop
codon location (and abnormally small proteins), and the insertion
from patient 12, c.768-769insG, deleted the wild-type stop codon
of the gene, producing a hyper-long protein. Mutations
c.172_176delTCGTA, c.370A>T, c.768-769insG, and c.313A>C
from patients 9, 11, 12, and 13/14, respectively, were not previ-
ously described in BPES. The methodology used did not show any
pathogenic mutations in 3 unrelated patients.
GenotypeeLacrimal Gland Phenotype
Association
Six distinct mutations were associated with a more severe lacrimal
phenotype, including absent or signiﬁcantly reduced LG size and
tear hyposecretion. These mutations comprised sequence variants
inducing premature stop codons (c.172_176delTCGTA,
c.919_920insACCGCCGC, and c.370A>T) or interfering with the
wild-type one (c.768-769insG), and missense mutations located in
the DNA-binding forkhead domain (c.292T>G, c.313A>C). The
Fisher exact test showed a higher probability for these mutations
to be associated with agenesis or underdevelopment of the gland
(P ¼ 0.021).
Lighter phenotypes, with LG volumes within or near control
group values and normal tear evaluation, were detected in associ-
ation with alanine expansions (c.672_701dup30) and a missense
mutation just before the polyalanine tract of the FOXL2 gene
(c.650C>G).
In 3 unrelated patients, the gene sequence was normal. Two of
these cases presented bilateral or unilateral LG agenesis (patients 3
and 4, respectively), and in the remaining one the gland was normal.402Discussion
The clinical presentation of BPES has been extensively
described.14 In addition to the classic signs of ptosis,
epicanthus inversus and telecanthus, a variety of
ophthalmic and nonophthalmic features15e20 are variably
associated with the syndrome. Deﬁciency of the tear
production apparatus has been overlooked. To our
knowledge, there are only 2 case reports of lacrimal
hyposecretion. Athappilly and Braverman21 described a
9-month-old female patient with BPES and bilateral
absence of the LG. More recently, another 9-month-old
infant with BPES was found to have absent tear production
though normal-sized LGs were visible on ultrasound
imaging.22
The present report is the ﬁrst to show that the association
between alacrima and BPES is not incidental. In our group
of patients, 52.3% had no measurable LGs (42.8% bilater-
ally and 9.5% unilaterally), and 33% of the remaining cases
showed reduced LG volume. Not surprisingly, there was a
clear association between these radiologic ﬁndings and tear
hyposecretion.
A genotypeephenotype correlation has not been proven
as yet in BPES.23 So far, more than 100 different mutations
have been described involving FOXL2, and pathogenic
variants can be found in approximately 88% of cases.24
The presence of other loci causing the syndrome also has
been proposed, although a clear association is still
lacking.17,25,26 We performed molecular screening of
FOXL2 in 16 patients to analyze speciﬁcally the LG
phenotype. Thirteen patients (81%) showed pathogenic
genetic changes, 4 of them already described by other
authors27-30 and the remaining 4 being novel mutations. The
most frequent mutation was a 30-nucleotide duplication
(c.672e 701dup30) causing an expansion of 10 alanine
residues (p.A224e234dup) within the polyalanine tract
(Fig 4). This mutation is responsible for a shift in the protein
location from the nucleus, where it is normally located, to
the cytoplasm, and induces a strong tendency to
aggregation.31 In our study, the same type of alanine
duplication was found in 2 distinct families (1 of them
Portuguese and the other Brazilian) and in 1 Brazilian
sporadic case. This genetic defect is, in fact, recurrent and
has been reported in distinct families with different
geographic and ethnic backgrounds.27
We found 3 missense mutations, 2 of them, c.650C>G
and c.292T>G, already known. The ﬁrst28 leads to a switch
from the amino acid serine to cysteine, immediately upstream
from the polyalanine domain. This substitution presumably
acts as a loss-of-function mutation, producing hypomorphic
or null alleles and haploinsufﬁciency.29 The latter is a change
from a tryptophan to a glycine within the forkhead domain of
FOXL2, a more common location for missense mutations in
BPES, and causes nuclear and cytoplasmic protein
aggregation.32 The third missense mutation (c.313A>C),
found in 2 related patients, is a novel pathogenic variant
and causes the substitution of an asparagine for a histidine
in the forkhead domain of FOXL2.24 The remaining 4
mutations included 2 insertions, c.919_920insACCGCCGC
Figure 2. From top to bottom: axial (left) and coronal (right) computed tomography (CT) scans of 4 distinct patients. Asterisks demonstrate absence of the
lacrimal gland (LG), curved arrows highlight reduced LG, and straight arrows indicate a normal-sized LG.
Duarte et al  Alacrima in Blepharophimosisand c.768-769insG, a nonsense mutation, c.370A>T, and a
deletion, c.172_176delTCGTA. Only the ﬁrst insertion has
been described.30
By taking into consideration only the LG phenotype and
the mutation data, our data suggest that there is an associ-
ation between the type of mutation and its location and LG
abnormality. This ﬁnding needs to be corroborated by the
evaluation of larger samples.
Overall, lower Schirmer scores in patients with BPES are
highly suspicious for LG underdevelopment or even
agenesia. The majority of patients with absent LG presentedsubnormal Schirmer scores. Nonetheless, 3 eyes with not
measurable LG displayed values above the 10-mm cut off.
We believe that these higher scores might be the result of the
presence of small amounts of lacrimal tissue indistinguish-
able in the CT scan. The LG is surrounded by numerous
structures with different radiologic densities, which make
the identiﬁcation of a small quantity of lacrimal tissue
difﬁcult, even for trained radiologists.
In the group of eyes with reduced LG volumes, Schirmer
scores were highly variable. One patient with very small
LGs (patient 11) presented low scores; however, in the403
Figure 3. Box-plot diagrams showing the right eye and left eye lacrimal
gland (LG) volume distribution in the control group (n ¼ 30) and patients
with blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) (n ¼
21). The central rectangle represents the interquartile range, the line inside
the rectangle represents the median, the small square indicates the mean,
and the whiskers above and below the box show the minimum and
maximum values. OD ¼ right eye; OS ¼ left eye.
Ophthalmology Volume 124, Number 3, March 2017remaining eyes there was not a clear relationship between
LG size and Schirmer test. Some eyes with near-normal LG
size displayed low Schirmer scores. When interpreting these
results, one should keep in mind the unreliable nature and
high variability of the Schirmer test.33 Besides that, our data
combined with a previous reported case of alacrima in aFigure 4. FOXL2 mutations causing blepharophimosis-ptosis-epicanthus inversu
protein product (II). Mutations in black ¼ mutations described in the current a
Forkhead domain, poly-ALA. B, Representative chromatograms of novel FO
deletion), N105H (missense), and P257Afs (in-frame 1 amino acid insertion).
404child with BPES and normal-sized LG22 might indicate
that FOXL2 mutations have an impact not only in the size
but also in the gland’s function.
Three patients (numbers 6, 7, and 20) displayed normal
LG volumes. Schirmer test was performed in 2 of these
patients with normal scores. We could not ﬁnd an association
between normal-sized LG and the molecular results. One of
the patients (number 6) did not have an identiﬁable mutation,
patient 7 presented the alanine expansion c.672e701dup30,
also associated with reduced size LG (Table 2), and in patient
20 the genetic screening was not performed.
The prevalence of LG underdevelopment in BPES
remains unknown. In a previous study involving clinical,
radiologic, and genetic analysis of 33 Indian patients with
BPES, Chawla et al17 used CT scans to study bone
development and to compare orbital biometry with
age-matched controls. No changes were detected in the
LGs, which were reported to be apparently normal. We
believe that a more accurate analysis of glandular volumes
probably could show signiﬁcant differences compared with
the age-matched control group. However, it is interesting to
notice that the rate of intragenic mutations in this group of
patients with BPES was only 4% (1/25), which is below the
usually reported rate of 72% in western countries.30 As
Chawla et al17 suggest, this may have an ethnic reason,
with the existence of other locus not yet described
responsible for this distinct genetic background.
Considering our results, we must emphasize the impor-
tance of LG agenesis for the surgical management of BPES.
There is a signiﬁcant burden for the parents of affected
children, who are usually extremely concerned about thes syndrome (BPES). A, Organization of the human FOXL2 gene (I) and its
rticle; mutations in red ¼ mutations previously described in the literature.
XL2 mutations. K124X (nonsense), S58RfsX36 (in-frame 5 amino acid
FD ¼ forkhead domain.
Duarte et al  Alacrima in Blepharophimosisabnormal appearance of the patients and exert a tremendous
pressure for early cosmetic rehabilitation. Although there is
no consensus about the best surgical strategy for the
correction of the multiple palpebral ﬁssure anomalies in
BPES,14 early ptosis surgery may be needed to alleviate the
chin position and avoid visual deprivation.34 Ptosis in BPES
is generally severe, with poor to zero levator function, and
most authors recommend bilateral frontalis slings.
Supramaximal levator resection35 and frontalis muscle
ﬂaps36,37 have been attempted with variable results. For
these reasons, a reduced tear production is a serious concern
for the long-term effects of ptosis correction on the ocular
surface, because it seems reasonable to accept that
spontaneous blink amplitude might be reduced after all
these different modalities of surgery.38 In addition, a certain
degree of nocturnal lagophthalmos is the rule after
congenital ptosis surgery, increasing the odds of corneal
complications. In our cohort, all patients with
demonstrable LG absence had persistent SPK; however,
we cannot ignore the inﬂuence of postsurgical
lagophthalmos in this corneal staining.
In conclusions, tear ﬁlm evaluation often is neglected in
children with BPES mainly because of the low position of
the upper lid and the lack of cooperation. Nevertheless, our
ﬁndings support the need for a careful preoperative evalu-
ation of the lacrimal production status in all patients with
BPES. If there is any sign of SPK or a history of tear
absence when crying, orbital imaging should be considered
to conﬁrm LG underdevelopment.
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